Generic Name: fluticasone furoate/vilanterol
Brand Name: Breo Ellipta
Manufacturer: GlaxoSmithKline Inc.
Therapeutic Area: Asthma
Indications: Asthma
Manufacturer Requested Reimbursement Criteria1: Breo Ellipta should be reimbursed preferentially to Advair to maximize asthma control in patients aged 18 years and older with reversible obstructive airways disease.
Submission Type: Resubmission
Project Status: Withdrawn
Biosimilar: No
Fee Schedule: Schedule B
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2 | |
|---|---|
| Call for patient input posted | April 04, 2018 |
| Patient group input closed | May 24, 2018 |
| Clarification: - No patient input submission received | |
| Submission received | May 02, 2018 |
| Submission accepted | May 16, 2018 |
| Review initiated | May 17, 2018 |
| Draft CADTH review report(s) sent to sponsor | August 01, 2018 |
| Comments from sponsor on draft CADTH review report(s) received | August 13, 2018 |
| Redaction requests from sponsor on draft CADTH review report(s) received | August 15, 2018 |
| Clarification: - Voluntarily withdrawn by the manufacturer on 2018-08-14 | |